Alector (ALEC) Stock Price, News & Analysis

Company Overview

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe.

Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide.

Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.

Key Stats

• Today's Range: $1.96 to $2.07
• 50-Day Range: $1.48 to $2.57
• 52-Week Range: $1.09 to $3.40
• Volume: 368,534 shs
• Average Volume: 923,237 shs
• Market Capitalization: $223.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.63
• Consensus Rating: Hold

Alector Stock Analysis - MarketRank™

Alector scored higher than 54% of companies evaluated by MarketBeat, and ranked 466th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Alector has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Alector has a consensus price target of $3.63, representing about 80.3% upside from its current price of $2.01.

Amount of Analyst Coverage

Alector has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alector are expected to grow in the coming year, from ($0.86) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alector is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alector is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alector has a P/B Ratio of 7.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.15% of the float of Alector has been sold short.

Short Interest Ratio / Days to Cover

Alector has a short interest ratio ("days to cover") of 7.64.

Change versus previous month

Short interest in Alector has recently increased by 3.18%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alector does not currently pay a dividend.

Dividend Growth

Alector does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Alector has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Alector this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for ALEC on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Alector to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,557.00 in company stock.

Percentage Held by Insiders

8.30% of the stock of Alector is held by insiders.

Percentage Held by Institutions

85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 7/01/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALEC
• CIK: 1653087
• Web: www.alector.com
• Phone: (415) 231-5660
• Fax: N/A
• Employees: 270
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Alector: $3.63
• High Price Target: $6.00
• Low Price Target: $1.50
• Potential Upside/Downside: +80.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$142.93 million
• Net Margins: -680.83%
• Pretax Margin: -679.91%
• Return on Equity: -295.17%
• Return on Assets: -40.95%

Debt

• Debt-to-Equity Ratio: 0.80
• Current Ratio: 5.25
• Quick Ratio: 5.25

Sales & Book Value

• Annual Sales: $21.05 million
• Price / Sales: 10.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 7.18

Miscellaneous

• Outstanding Shares: 111,030,000
• Free Float: 101,810,000
• Market Cap: $223.17 million
• Optionable: Optionable
• Beta: 0.60